Berg KH, et al. - A total of 360 (240 men, 120 women) axial spondyloarthritis (axSpA) patients were included in order to explore the association between demographics, disease-related variables, treatment, and sexual quality of life (SQOL) in men and women with axSpA. Mean (SD) values for disease measures were C-reactive protein (CRP) 8.5 mg/l, Bath Ankylosing Spondylitis Disease Activity Index 3.1, Bath Ankylosing Spondylitis Global Score (BAS-G) 3.8, Bath Ankylosing Spondylitis Functional Index 2.7, and Health Assessment Questionnaire 0.6. The proportion of patients using NSAIDs was 44.0%, synthetic disease-modifying antirheumatic drugs (DMARD) 5.0%, and biologic DMARD 24.0%. Mean (SD) total sum score for SQOL was 76.6. In multivariate analysis, female gender, elevated BMI, measures reflecting disease activity (BAS-G and CRP), and prevailing biologic treatment were independently related to a lower SQOL. Therefore, via the above findings, it was inferred that inflammation in patients with axSpA even in the biologic treatment era decreases SQOL.